Reata (UT Southwestern) and Abbott Announce Positive Phase 2b Study Results for Bardoxolone Methyl (11/20/2010)

Reata Pharmaceuticals is a biopharmaceutical company focused on intractable diseases. Two of the company’s founding scientists are Dr. Philip J. Thomas (Professor of Physiology at UT Southwestern Medical Center) and current Vice President of Reserch W. Christian Wigley, Ph.D. (formerly Senior Research Scientist in the Department of Physiology at UT Southwestern Medical Center).

From the company’s press release:
Reata Pharmaceuticals and Abbott today announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other measures of kidney function in the majority of patients receiving the drug. The data were presented today in a late-breaking oral presentation at the American Society of Nephrology (ASN) Renal Week Conference in Denver, Colorado. read full press release


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: